Αρχική World News FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for... World News FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC Από Ogkologos - 16 Οκτωβρίου, 2025 450 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... 6 Δεκεμβρίου, 2021 Cancer-impacted mother becomes Times Square billboard to help child come across... 21 Ιουλίου, 2023 Dad Is Making Baby Giggle, But When He Makes A Sheep... 21 Μαΐου, 2019 Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... 2 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Blood test could tailor treatment after surgery Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... How to Strengthen Your Immune System: Part 1 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab...